Open AccessAnti-IgE Therapy with Omalizumab Decreases Endothelin-1 in Exhaled Breath Condensate of Patients with Severe Persistent Allergic Asthma
Author(s) -
Ziemowit Ziętkowski,
Roman Skiepko,
Maria Magdalena Tomasiak,
Anna BodzentaŁukaszyk
Publication year - 2010
Publication title -
respiration
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.264
H-Index - 81
eISSN - 1423-0356
pISSN - 0025-7931
DOI - 10.1159/000317137
Subject(s) - omalizumab , medicine , exhaled breath condensate , exhaled nitric oxide , asthma , eosinophil , immunoglobulin e , spirometry , eosinophil cationic protein , gastroenterology , benralizumab , immunology , mepolizumab , antibody
Omalizumab is a humanized monoclonal anti-IgE antibody, especially useful for the treatment of severe persistent allergic asthma, inadequately controlled despite regular therapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom